NCT07468656
SCLC Tarlatamab Blood Collection
Registry fields
- Overall status
- NOT_YET_RECRUITING
- Conditions
- Small-cell Lung Cancer
- Study type
- OBSERVATIONAL
- Lead sponsor
- Duke University (OTHER)
Cached at: 2026-08-06 08:34:49
Brief summary
The overall objective of this project is to prospectively collect blood samples throughout treatment with tarlatamab in patients with small cell lung cancer (SCLC). These samples will then be analyzed through a variety of assays to better characterize tarlatamab in the real-world setting.
The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
The investigators will prospectively collect blood samples from 25 patients on days 1, 8, and 15 of tarlatamab treatment, as well as after each interval scan for disease monitoring. The investigators will also collect patient data including demographics and baseline characteristics, primary diagnosis, treatment history, and disease monitoring and progression.
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue